The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Anktiva (nogapendekin alfa inbakicept) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Joseph Jacob, MD, discusses the promising impact of TAR-200.

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

Multidisciplinary care, a collaborative approach where various healthcare disciplines come together, is essential for treating those with prostate cancer.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with ...

Bladder removal surgery is beneficial when a patient does not respond to other treatment options and when the cancer is ...